Randomized Phase IIb Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma (RCC).

Trial Profile

Randomized Phase IIb Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma (RCC).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2015

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Aug 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 19 Jul 2011 Actual end date (Apr 2011) added as reported by ClinicalTrials.gov.
    • 19 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top